Genedrive Raises £5.26 Million to Bolster Point-of-Care Pharmacogenetics Push

An update from Genedrive ( (GB:GDR) ) is now available.

Genedrive plc, a UK-listed point-of-care pharmacogenetic testing specialist, focuses on rapid, low-cost genetic diagnostics that enable clinicians to tailor drug choice and dosage, with particular emphasis on emergency healthcare settings. The company’s key products are the Genedrive MT-RNR1 ID Kit, used to guide neonatal antibiotic use, and the Genedrive CYP2C19 ID Kit, both delivered via disposable, ambient-stable cartridges on its own thermocycler platform.

Genedrive has conditionally raised approximately £0.91 million through an open offer that was 60.7% taken up by qualifying shareholders, and an additional £0.35 million via further subscriptions from investors who could not fully participate in the earlier placing or offer. Including the firm and conditional subscriptions, placing, open offer, additional subscriptions and loan conversion, the company expects to raise £5.26 million before expenses—around £4.9 million net—subject to shareholder approval and admission of 515,964,264 new shares, which will take its total share count to 1,605,568,256.

Major shareholders David Nugent and Robert English have supported the enlarged fundraising, while CEO Dr. Gino Miele and CFO Russ Shaw participated in the open offer as related parties, with the board deeming their involvement fair and reasonable following adviser consultation. The strengthened capital base is intended to support execution of Genedrive’s strategy in point-of-care pharmacogenetics, potentially reinforcing its market position and providing additional runway to commercialise its testing platform and expand uptake of its flagship kits.

The most recent analyst rating on (GB:GDR) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.

Spark’s Take on GB:GDR Stock

According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.

The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and a shrinking equity base despite minimal debt. Technicals are moderately supportive with price above key moving averages and positive MACD, but elevated RSI signals near-term overheating risk. Valuation remains challenging due to negative earnings (negative P/E).

To see Spark’s full report on GB:GDR stock, click here.

More about Genedrive

Genedrive plc is a UK-based pharmacogenetic testing company that develops and commercialises low-cost, rapid, point-of-care genetic tests to guide personalised medicine decisions, particularly in time-critical emergency care. Its flagship MT-RNR1 and CYP2C19 ID kits, developed with NHS partners, run on a proprietary thermocycler platform using single-use, ambient-stable cartridges that avoid cold-chain logistics and support safer, more effective treatment choices.

Average Trading Volume: 6,186,959

Technical Sentiment Signal: Sell

Current Market Cap: £11.6M

Learn more about GDR stock on TipRanks’ Stock Analysis page.